Hudson Bay Capital Management
DRMAW icon

Hudson Bay Capital Management’s Dermata Therapeutics Warrant DRMAW Stock Holding History

Hudson Bay Capital Management’s Portfolio DRMAW Stock Details DRMAW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-75,000
Closed -$62K – 1115
2021
Q3 		$62K Buy
+75,000
New +$77K ﹤0.01% 920

Other funds holding DRMAW

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
EAM
Empery Asset Management New York $83M AUM
WAM
Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Hudson Bay Capital Management's DRMAW Position: Q4 2021 in Review

Hudson Bay Capital Management sold out of Dermata Therapeutics Warrant (DRMAW) in Q4 2021, closing a stake of 75,000 shares — an estimated $62K sold.

Hudson Bay Capital Management first reported a position in DRMAW in Q3 2021 and held it in 1 quarter. The position peaked at $62K in Q3 2021. 6 funds tracked by Wall St. Rank hold DRMAW as of Q4 2021.

  • Hudson Bay Capital Management reported no remaining Dermata Therapeutics Warrant position as of Q4 2021 after selling out during the quarter.
  • Hudson Bay Capital Management sold 75,000 Dermata Therapeutics Warrant shares in Q4 2021, an estimated $62K.
  • Hudson Bay Capital Management first reported a position in Dermata Therapeutics Warrant in Q3 2021 and held it in 1 quarter.
  • Hudson Bay Capital Management's Dermata Therapeutics Warrant position peaked at $62K in Q3 2021.
  • 6 funds tracked by Wall St. Rank held Dermata Therapeutics Warrant as of Q4 2021.

Based on Hudson Bay Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.